ArticleNature cancer2022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
Víctor A Arrieta et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it